74 results
6-K
EX-99.1
ENLV
Enlivex Therapeutics Ltd
18 May 20
Condensed Consolidated Financial Statements
4:30pm
royalties to the State of Israel (represented by the Israel Innovation Authority), computed on the basis of proceeds from the sale or license of products … the Israel Innovation Authority to such date, including accrued interest. As of March 31, 2020, the Company had not paid any royalties to the Israel
6-K
EX-99.2
ENLV
Enlivex Therapeutics Ltd
30 Oct 20
Condensed Consolidated Financial Statements
4:30pm
revenue. We have funded our operations primarily through grants from the Israel Innovation Authority and pursuant to the sale of equity and equity … product candidates for potential commercialization. Furthermore, although we expect to obtain additional grants from the Israel Innovation Authority, we
6-K
EX-99.1
ENLV
Enlivex Therapeutics Ltd
25 May 22
Enlivex Awarded Its Third Non-Dilutive Israel Innovation Authority Grant
8:05am
Exhibit 99.1
Enlivex Awarded Its Third Non-Dilutive Israel Innovation Authority Grant
to Support the Clinical Development of Allocetra in Sepsis … million in non-dilutive grants from the Israel Innovation Authority, excluding this new grant
Nes Ziona, Israel, May 25, 2022 (GLOBE NEWSWIRE
6-K
EX-99.2
ENLV
Enlivex Therapeutics Ltd
14 Aug 20
Condensed Consolidated Financial Statements
4:23pm
any revenue. We have funded our operations primarily through grants from the Israel Innovation Authority and pursuant to the sale of equity … additional grants from the Israel Innovation Authority, we cannot be certain that we will do so. Clinical development timelines, the probability of success
6-K
EX-99.1
ENLV
Enlivex Therapeutics Ltd
14 Aug 20
Condensed Consolidated Financial Statements
4:23pm
7 –
COMMITMENTS AND CONTINGENCIES
The Company is required to pay royalties to the State of Israel (represented by the Israel Innovation Authority … the gross amount of grants actually received by the Company from the Israel Innovation Authority to such date, including accrued interest. As of June 30
6-K/A
EX-99.2
wnemkg3dgmg
13 Oct 20
Condensed Consolidated Financial Statements
9:16am
6-K/A
EX-99.1
635omoodlw15v5h6lgd
13 Oct 20
Condensed Consolidated Financial Statements
9:16am
6-K
EX-99.1
kenilhva49nky0
30 Oct 20
Condensed Consolidated Financial Statements
4:30pm
6-K
EX-99.2
r74jcc tt8mc79er
18 May 20
Condensed Consolidated Financial Statements
4:30pm
6-K
EX-99.2
k73uysv0 e5bx
14 Nov 19
Condensed Consolidated Financial Statements
7:30am
6-K
EX-99.2
4tubhubx2yytc4p
26 Jul 19
Condensed Consolidated Financial Statements
4:32pm
6-K
EX-99.1
knq3s
20 May 19
Condensed Consolidated Financial Statements
4:15pm
6-K
EX-99.1
cqto5vhl o01
14 Nov 19
Condensed Consolidated Financial Statements
7:30am
6-K
EX-99.1
3yzgu0
13 Apr 20
Enlivex Selected by the Israel Innovation Authority to Receive $1.5 Million Grant to Fund COVID-19 and Sepsis Clinical Trials
8:32am
6-K
EX-99.1
6cptxdqrvgzte 5fd8
26 Jul 19
Condensed Consolidated Financial Statements
4:32pm
6-K
EX-99.1
8fiu51
18 May 21
Enlivex Awarded Second Israel Innovation Authority Grant to Support the Clinical Development of Allocetra in Sepsis
8:03am
6-K
EX-99.2
7als0gw
20 May 19
Condensed Consolidated Financial Statements
4:15pm
6-K
EX-99.2
amolmc49w1 z0twk8lp
6 Aug 21
Condensed Consolidated Financial Statements
4:31pm
6-K
EX-99.2
59z4f7koitb
28 May 21
Condensed Consolidated Financial Statements
4:33pm
6-K
EX-99.2
90dtjej1u4 dum
27 May 22
Condensed Consolidated Financial Statements
4:39pm